GlaxoSmithKline Pharmaceuticals reports Q1 FY26 PAT at Rs. 205 Cr
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
This year, the OCTF focused on preparing a white paper on oral cancer elimination in India and updating its annual consensus guidelines
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision
This partnership aims to address the growing demand for high-quality diagnostics in metropolitan areas
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
A triple-action Formula for comprehensive respiratory relief
mRNA-1010 demonstrated superior relative vaccine efficacy
Subscribe To Our Newsletter & Stay Updated